Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mäkinen N[au]:

Search results

Items: 22

1.

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers.

Hänninen UA, Wirta EV, Katainen R, Tanskanen T, Hamberg J, Taipale M, Böhm J, Renkonen-Sinisalo L, Lepistö A, Forsström LM, Pitkänen E, Palin K, Seppälä TT, Mäkinen N, Mecklin JP, Aaltonen LA.

Br J Cancer. 2019 Apr;120(9):922-930. doi: 10.1038/s41416-019-0427-4. Epub 2019 Mar 21.

PMID:
30894686
2.

Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.

Ahvenainen TV, Mäkinen NM, von Nandelstadh P, Vahteristo MEA, Pasanen AM, Bützow RC, Vahteristo PM.

Cancer. 2018 Dec 15;124(24):4650-4656. doi: 10.1002/cncr.31754. Epub 2018 Nov 13.

PMID:
30423196
3.

Exome-wide somatic mutation characterization of small bowel adenocarcinoma.

Hänninen UA, Katainen R, Tanskanen T, Plaketti RM, Laine R, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin JP, Forsström LM, Pitkänen E, Palin K, Välimäki N, Mäkinen N, Aaltonen LA.

PLoS Genet. 2018 Mar 9;14(3):e1007200. doi: 10.1371/journal.pgen.1007200. eCollection 2018 Mar.

4.

Global metabolomic profiling of uterine leiomyomas.

Heinonen HR, Mehine M, Mäkinen N, Pasanen A, Pitkänen E, Karhu A, Sarvilinna NS, Sjöberg J, Heikinheimo O, Bützow R, Aaltonen LA, Kaasinen E.

Br J Cancer. 2017 Dec 5;117(12):1855-1864. doi: 10.1038/bjc.2017.361. Epub 2017 Oct 26.

5.

Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.

Mäkinen N, Kämpjärvi K, Frizzell N, Bützow R, Vahteristo P.

Mol Cancer. 2017 Jun 7;16(1):101. doi: 10.1186/s12943-017-0672-1.

6.

Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.

Heinonen HR, Pasanen A, Heikinheimo O, Tanskanen T, Palin K, Tolvanen J, Vahteristo P, Sjöberg J, Pitkänen E, Bützow R, Mäkinen N, Aaltonen LA.

Sci Rep. 2017 Apr 21;7(1):1015. doi: 10.1038/s41598-017-01199-0.

7.

Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry.

Heikkinen T, Kämpjärvi K, Keskitalo S, von Nandelstadh P, Liu X, Rantanen V, Pitkänen E, Kinnunen M, Kuusanmäki H, Kontro M, Turunen M, Mäkinen N, Taipale J, Heckman C, Lehti K, Mustjoki S, Varjosalo M, Vahteristo P.

Hum Mutat. 2017 Mar;38(3):269-274. doi: 10.1002/humu.23157. Epub 2017 Jan 11.

PMID:
28054750
8.

MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.

Kämpjärvi K, Mäkinen N, Mehine M, Välipakka S, Uimari O, Pitkänen E, Heinonen HR, Heikkinen T, Tolvanen J, Ahtikoski A, Frizzell N, Sarvilinna N, Sjöberg J, Bützow R, Aaltonen LA, Vahteristo P.

Br J Cancer. 2016 Jun 14;114(12):1405-11. doi: 10.1038/bjc.2016.130. Epub 2016 May 17.

9.

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R, Vahteristo P.

PLoS Genet. 2016 Feb 18;12(2):e1005850. doi: 10.1371/journal.pgen.1005850. eCollection 2016 Feb.

10.

Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.

Mehine M, Kaasinen E, Heinonen HR, Mäkinen N, Kämpjärvi K, Sarvilinna N, Aavikko M, Vähärautio A, Pasanen A, Bützow R, Heikinheimo O, Sjöberg J, Pitkänen E, Vahteristo P, Aaltonen LA.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1315-20. doi: 10.1073/pnas.1518752113. Epub 2016 Jan 19.

11.

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

Kämpjärvi K, Kim NH, Keskitalo S, Clark AD, von Nandelstadh P, Turunen M, Heikkinen T, Park MJ, Mäkinen N, Kivinummi K, Lintula S, Hotakainen K, Nevanlinna H, Hokland P, Böhling T, Bützow R, Böhm J, Mecklin JP, Järvinen H, Kontro M, Visakorpi T, Taipale J, Varjosalo M, Boyer TG, Vahteristo P.

Prostate. 2016 Jan;76(1):22-31. doi: 10.1002/pros.23092. Epub 2015 Sep 18.

PMID:
26383637
12.

Clonally related uterine leiomyomas are common and display branched tumor evolution.

Mehine M, Heinonen HR, Sarvilinna N, Pitkänen E, Mäkinen N, Katainen R, Tuupanen S, Bützow R, Sjöberg J, Aaltonen LA.

Hum Mol Genet. 2015 Aug 1;24(15):4407-16. doi: 10.1093/hmg/ddv177. Epub 2015 May 10.

PMID:
25964426
13.

MED12 mutation frequency in unselected sporadic uterine leiomyomas.

Heinonen HR, Sarvilinna NS, Sjöberg J, Kämpjärvi K, Pitkänen E, Vahteristo P, Mäkinen N, Aaltonen LA.

Fertil Steril. 2014 Oct;102(4):1137-42. doi: 10.1016/j.fertnstert.2014.06.040. Epub 2014 Aug 6.

PMID:
25108465
14.

Genomics of uterine leiomyomas: insights from high-throughput sequencing.

Mehine M, Mäkinen N, Heinonen HR, Aaltonen LA, Vahteristo P.

Fertil Steril. 2014 Sep;102(3):621-9. doi: 10.1016/j.fertnstert.2014.06.050. Epub 2014 Aug 5. Review.

PMID:
25106763
15.

Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.

Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, Mäkinen N, Gao F, Palin K, Nurkkala H, Vähärautio A, Aavikko M, Kämpjärvi K, Vahteristo P, Kim CA, Aaltonen LA, Varjosalo M, Taipale J, Boyer TG.

Cell Rep. 2014 May 8;7(3):654-60. doi: 10.1016/j.celrep.2014.03.047. Epub 2014 Apr 18.

16.

Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.

Mäkinen N, Heinonen HR, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA.

Br J Cancer. 2014 Apr 29;110(9):2246-9. doi: 10.1038/bjc.2014.138. Epub 2014 Mar 18.

17.

Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.

Mäkinen N, Vahteristo P, Bützow R, Sjöberg J, Aaltonen LA.

Int J Cancer. 2014 Feb 15;134(4):1008-12. doi: 10.1002/ijc.28410. Epub 2013 Aug 29.

18.

Characterization of uterine leiomyomas by whole-genome sequencing.

Mehine M, Kaasinen E, Mäkinen N, Katainen R, Kämpjärvi K, Pitkänen E, Heinonen HR, Bützow R, Kilpivaara O, Kuosmanen A, Ristolainen H, Gentile M, Sjöberg J, Vahteristo P, Aaltonen LA.

N Engl J Med. 2013 Jul 4;369(1):43-53. doi: 10.1056/NEJMoa1302736. Epub 2013 Jun 5.

19.

MED12 exon 2 mutations in histopathological uterine leiomyoma variants.

Mäkinen N, Vahteristo P, Kämpjärvi K, Arola J, Bützow R, Aaltonen LA.

Eur J Hum Genet. 2013 Nov;21(11):1300-3. doi: 10.1038/ejhg.2013.33. Epub 2013 Feb 27.

20.

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.

Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari LM, Mehine M, Schrewe H, Nevanlinna H, Levine RL, Hokland P, Böhling T, Mecklin JP, Bützow R, Aaltonen LA, Vahteristo P.

Br J Cancer. 2012 Nov 6;107(10):1761-5. doi: 10.1038/bjc.2012.428. Epub 2012 Sep 20.

21.

MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.

Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA.

Oncotarget. 2011 Dec;2(12):966-9.

22.

MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.

Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA.

Science. 2011 Oct 14;334(6053):252-5. doi: 10.1126/science.1208930. Epub 2011 Aug 25.

Supplemental Content

Loading ...
Support Center